ClinicalTrials.gg
CompletedNCT00242320Updated Dec 2, 2016

Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)

A Phase 3 interventional study of Roflumilast and Placebo in COPD, sponsored by AstraZeneca. Completed at 33 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-12-02.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
551
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
14th of 32
551 · median 154
Started
2005
with 1 other
Phase 3
16 of 32
none open now
Registered
4th of 32
by date
Lead sponsor
18 of 32
AstraZeneca

Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 14th largest by enrollment, is one of 2 that started in 2005, is one of 16 in phase 3, and was the 4th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The aim of the study is to compare the effect of roflumilast on lung function in patients with COPD. Roflumilast will be administered orally once daily in the morning at one dose level. The study duration consists of a baseline period (4 weeks) and a treatment period (12 weeks). The study will provide further data on safety and tolerability of roflumilast.

03

Conditions studied

  • COPD

Keywords

  • COPD
  • chronic obstructive pulmonary disease
  • Roflumilast
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Written
  • Patients with a history of (COPD) as defined by the GOLD criteria (2003)
  • /FVC ratio (post bronchodilator) smaller or equal 70%
  • FEV1 (post bronchodilator) 30-80% of predicted
  • Fixed airway obstruction
  • Current smoker or former smoker (smoking cessation at least one year ago) with a smoking history of at least 10 pack years
  • Clinically stable COPD within 4 weeks prior to baseline visit
  • Availability of a chest x-ray

Main Exclusion Criteria:

  • COPD exacerbation indicated by a treatment with systemic glucocorticosteroids
  • Lower respiratory tract infection
  • Diagnosis of asthma
  • Known alpha-1-antitrypsin deficiency
  • Need for long term oxygen therapy defined as longer or equal 16 hours/day
  • abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation (as assessed by the investigator)
  • Known infection with , active hepatitis and/or liver insufficiency (according to the score A or worse)
  • Diagnosis or history of cancer
  • Clinically significant cardiopulmonary abnormalities
  • Pregnancy, breast feeding, oocyte donation or oocyte implantation planned during the trial
  • Female patients of , not using reliable method of for the entire study duration, > 1 year or who are not using any other method considered sufficiently reliable by the investigator in individual cases
  • Participation in another study (use of product) within 30 days preceding the baseline visit or re-entry of patients already enroled in this trial
  • Alcohol or drug abuse
  • Inability to follow the study procedures due to e.g., language problems, physiological disorders
  • Use of not allowed drugs
  • Suspected to the study medication or rescue medication
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
551 participants (actual)

Study arms

  • Active comparator
    1

    Roflumilast 500 µg

    Drug: Roflumilast

  • Placebo comparator
    2

    Placebo

    Drug: Roflumilast · Drug: Placebo

Interventions

  • to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. mean change from randomization to endpoint in lung function (post bronchodilator)

    Time frame: 12 weeks

Secondary outcomes

  1. mean change from randomization to endpoint in pre and post bronchodilator spirometric parameters

    Time frame: 12 weeks

  2. exacerbation rate

    Time frame: 12 weeks

  3. adverse events

    Time frame: 12 weeks

  4. changes in laboratory values

    Time frame: 12 weeks

  5. changes in vital signs

    Time frame: 12 weeks

07

Study locations

33 sites
  • Altana Pharma/Nycomed
    Hong Kong, 852, Hong Kong
  • Altana Pharma/Nycomed
    Shatin, NT, Hong Kong, Hong Kong
  • Altana Pharma/Nycomed
    Anvang-Si, Gveonggi-Do, 431-070, Korea, Republic of
  • Altana Pharma/Nycomed
    Chungbuk, 361-711, Korea, Republic of
  • Altana Pharma/Nycomed
    Gangwon-do, 220-701, Korea, Republic of
  • Altana Pharma/Nycomed
    Gangwon-Do, 220-711, Korea, Republic of
  • Altana Pharma/Nycomed
    Gwangju, 501-757, Korea, Republic of
  • Altana Pharma/Nycomed
    Gyeonggi-do, 420-767, Korea, Republic of
  • Altana Pharma/Nycomed
    Jiniu-Si. Gveongsangnam-Do, 660-702, Korea, Republic of
  • Altana Pharma/Nycomed
    Seoul, 135-720, Korea, Republic of
  • Altana Pharma/Nycomed
    Seoul, 136-705, Korea, Republic of
  • Altana Pharma/Nycomed
    Seoul, 137-701, Korea, Republic of
  • Altana Pharma/Nycomed
    Seoul, 138-736, Korea, Republic of
  • Altana Pharma/Nycomed
    Seoul, 140-757, Korea, Republic of
  • Altana Pharma/Nycomed
    Seoul, 158-710, Korea, Republic of
  • Altana Pharma/Nycomed
    Uijongbu-city, Gveonggi-Do, 480-130, Korea, Republic of
  • Altana Pharma/Nycomed
    Ulsan, 682-060, Korea, Republic of
  • Altana Pharma/Nycomed
    Jalan Rasah, Seremban, 70300, Malaysia
  • Altana Pharma/Nycomed
    Kota Bharu / Kelantan, 16150, Malaysia
  • Altana Pharma/Nycomed
    Kota Kinabalu, Sabah, 88586, Malaysia
  • Altana Pharma/Nycomed
    Kuala Lumpur, 50590, Malaysia
  • Altana Pharma/Nycomed
    Kuala Lumpur, 56000, Malaysia
  • Altana Pharma/Nycomed
    Kuala Lumpur, 59100, Malaysia
  • Altana Pharma/Nycomed
    Manila, 1000, Philippines
  • Altana Pharma/Nycomed
    Quezon City, 1100, Philippines
  • Altana Pharma/Nycomed
    Quezon City, 1102, Philippines
  • Altana Pharma/Nycomed
    Quezon City, 850, Philippines
  • Altana Pharma/Nycomed
    Quezon City, 870, Philippines
  • Altana Pharma/Nycomed
    Kaohsiung, 886-807, Taiwan
  • Altana Pharma/Nycomed
    Taipei City 114, 886-114, Taiwan
  • Altana Pharma/Nycomed
    Taipei, 886-114, Taiwan
  • Altana Pharma/Nycomed
    Taipei, Taiwan
  • Altana Pharma/Nycomed
    Tau-Yuan, 886-333, Taiwan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of May 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2005
First posted
Oct 20, 2005
Start
Aug 2005
Primary completionActual
May 2007
CompletionActual
Aug 2007
Last update
Dec 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00242320
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 20, 2005
Start date
Aug 2005
Primary completion
May 2007
Completion
Aug 2007
Last update
Dec 2, 2016

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion